文献速递乳腺癌

风险适应优化HER2阳性早期乳腺癌新辅助治疗

Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer.
PubMed 文献 · J Clin Oncol · 2026-09-09

本文综述支持在II期HER2阳性早期乳腺癌新辅助治疗中降阶梯的证据,包括可安全省略卡铂、从多西他赛或紫杉醇+卡铂+双靶向降阶梯为紫杉醇+双靶向,并讨论基于生物标志物的无化疗策略。DESTINY-Breast11和DESTINY-Breast05确立了德曲妥珠单抗在高危疾病中新辅助及后辅助的新选择,两者近期获FDA批准。作者提出风险适应治疗优化框架,强调循环肿瘤DNA监测和功能成像作为反应适应策略的潜力。

要点

  • II期HER2阳性早期乳腺癌新辅助治疗可安全省略卡铂,病理完全缓解率相当且毒性降低。
  • 支持从多西他赛或紫杉醇+卡铂+曲妥珠单抗+帕妥珠单抗降阶梯为紫杉醇+双靶向治疗。
  • 德曲妥珠单抗已获FDA批准用于高危疾病的新辅助和后辅助治疗。

核心结论

  • 风险适应降阶梯策略支持对II期HER2阳性早期乳腺癌省略卡铂并简化化疗 backbone。
  • 德曲妥珠单抗在高危疾病中新辅助和后辅助治疗中确立为新选择并获FDA批准。
  • 循环肿瘤DNA监测和功能成像是有前景的反应适应策略,为未来研究重点。

研究设计与样本

  • 本文为综述,汇总随机试验数据及DESTINY-Breast11和DESTINY-Breast05等研究证据。

主要发现

  • 随机试验数据显示,对大多数II期HER2阳性早期乳腺癌患者,新辅助治疗省略卡铂后病理完全缓解率相当且毒性降低。
  • DESTINY-Breast11和DESTINY-Breast05分别确立了德曲妥珠单抗在新辅助和后辅助治疗中用于高危疾病的新选择。

临床怎么用

  • 对II期HER2阳性早期乳腺癌可考虑省略卡铂以降低毒性。
  • 可考虑从多西他赛或紫杉醇+卡铂+双靶向降阶梯为紫杉醇+双靶向治疗。
  • 高危患者可选用德曲妥珠单抗作为新辅助或后辅助治疗。
  • 可探索循环肿瘤DNA监测和功能成像指导反应适应治疗。

局限性

  • 本文为综述,未报告原始研究的具体样本量、P值等数据。
  • 循环肿瘤DNA监测和功能成像作为反应适应策略的潜力仍需未来研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Women with stage II to III human epidermal growth factor receptor 2 (HER2)-positive breast cancer commonly receive neoadjuvant therapy. Recent trials have substantially expanded treatment options for these individuals. Randomized trial data indicate that carboplatin can be safely omitted from neoadjuvant therapy for most patients with stage II HER2-positive early-stage breast cancer, with comparable pathological complete response rates and reduced toxicity. Here, we review evidence supporting de-escalation in the neoadjuvant setting from docetaxel or paclitaxel, carboplatin, trastuzumab, pertuzumab to docetaxel or paclitaxel, trastuzumab, pertuzumab with weekly paclitaxel and examine biomarker-guided strategies for further de-escalation, including chemotherapy-free approaches. DESTINY-Breast11 and DESTINY-Breast05 have established the use of neoadjuvant and postneoadjuvant fam-trastuzumab deruxtecan-nxki, respectively, as new options for high-risk disease, with both indications recently granted approval from the US Food and Drug Administration. We propose a framework for risk-adapted treatment optimization, highlighting the potential of circulating tumor DNA monitoring and functional imaging as response-adapted strategies and identifying them as priorities for future investigation. Together, these advances support a more precise, individualized approach to caring for patients with early-stage HER2-positive breast cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kleeman SO, Stearns V. Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer. J Clin Oncol. 2026. PMID: 42715513. doi:10.1200/JCO-26-01423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。